Browse our anti-NFKBIB (NFKBIB) Antibodies

Mouse (Murine) Nuclear Factor of kappa Light Polypeptide Gene Enhancer in B-Cells Inhibitor, beta (NFKBIB) interaction partners

1. IkappaBbeta has essential functions within the Rel-NFkappaB generation module, specifically for the RelA:RelA homodimer, which controls a subset of NFkappaB target genes.

2. these results mechanistically link the innate immune response mediated by IkappaBbeta/NF-kappaB (show NFKB1 Antibodies) to ET-1 (show EDN1 Antibodies) expression and potentially reveal therapeutic targets for patients with Gram-negative septic shock.

3. Dengue virus protease interacts with both IkappaBalpha (show NFKBIA Antibodies) and IkappaBbeta cleaving them in a mouse hemorrhage model.

4. sustained NF-kappaB (show NFKB1 Antibodies) activity mediated by IkappaBbeta protects against hyperoxic lung injury through increased expression of antiapoptotic genes

5. Findings represent a necessary but not sufficient role of IkappaBbeta in preventing oxidant stress-induced cell death.

6. IkappaBbeta is an essential co-activator for LPS (show TLR4 Antibodies)-induced IL-1beta (show IL1B Antibodies) transcription in vivo.

7. IkappaBbeta acts through p65 (show NFkBP65 Antibodies):c-Rel (show NFkBP65 Antibodies) dimers to maintain prolonged expression of TNF-alpha (show TNF Antibodies)

8. data suggest that RelA (show NFkBP65 Antibodies) is liberated during LPS (show TLR4 Antibodies)-induced pulmonary inflammation by the regulated degradation of both IkappaB-alpha (show NFKBIA Antibodies) and IkappaB-beta

9. temporal control of NF-kappaB (show NFKB1 Antibodies) activation by the coordinated degradation and synthesis of IkappaB proteins

10. beta-TrCP1 (show BTRC Antibodies) contributes to, but is not absolutely required for, the degradation of I kappa B and beta-catenin (show CTNNB1 Antibodies)

Human Nuclear Factor of kappa Light Polypeptide Gene Enhancer in B-Cells Inhibitor, beta (NFKBIB) interaction partners

1. The subcellular distributions of IkappaB and NFkappaB are indicative of carcinogenesis. Inhibition of XPO1 results in intranuclear retention of IkappaB, which inhibits NFkappaB and thereby provides a novel mechanism for drug therapy in sarcoma. This effect can be further enhanced in relatively selinexor-resistant sarcoma cell lines by pretreatment with the proteasome inhibitor carfilzomib.

2. data suggest that miRNA-4776 modulates Influenza A virus production in infected cells through NFKBIB expression, possibly through the modulation of NF-kappaB (show NFKB1 Antibodies).

3. our data establish the importance of a novel tumor suppressive IKBB gene in abrogating angiogenesis in NPC (show NPC1 Antibodies) via the NF-kappaB (show NFKB1 Antibodies) signalling pathway.

4. IkappaBbeta may be a novel target for transcription factors of the HMG (show SSRP1 Antibodies)-box SRY (show SRY Antibodies)/Sox (show PIPOX Antibodies) family and imply a potential role for NF-kappaB (show NFKB1 Antibodies)/IkappaBbeta in spermatogenesis

5. Data show that increased nuclear factor-kappaB (NF-kB) activity in the amnion during labor is associated with an increase in the expression of NF-kBp65 and of the NF-kB binding proteins IkBa (show NFKBIA Antibodies), IkBb-1 and IkBb-2.

6. VEGF (show VEGFA Antibodies) increased Mn-superoxide dismutase (show SOD2 Antibodies) promoter activity, an effect that was dependent on a second intronic NF-kappaB (show NFKB1 Antibodies) consensus motif.

7. data indicate that inhibition of NFkappa-B activity by the hepatitis C virus core protein might be related to its physical interaction with and interrupted nuclear localization of IKKbeta (show IKBKB Antibodies)

8. None of the NFKBIB SNPs are associated with pneumococcal susceptibility.

9. NF-kappaB (show NFKB1 Antibodies), IkappaB-alpha (show NFKBIA Antibodies), IkappaB-beta mRNA decreased significantly after weight loss.

10. increased I-kappaBbeta expression reversed NF-kappaB (show NFKB1 Antibodies) activation in cancer cells, compensating for the loss of I-kappaBalpha (show NFKBIA Antibodies) via TGase 2 (show TGM2 Antibodies) polymerization.